Use of Hydroxychloroquine in Hair Disorders
© 2023 S. Karger AG, Basel..
Hydroxychloroquine (HCQ) is an antimalarial that is utilized to treat a range of dermatologic and autoimmune disorders. With its ability to alter immunologic mechanisms, it has been used to slow or halt the progression of hair loss in conditions secondary to autoimmune dysfunction. Lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and alopecia areata (AA) are hair disorders with underlying autoimmune components and no standardized treatment guidelines. We summarized the available literature on the use of HCQ to treat LPP, FFA, and AA. For all three conditions, HCQ showed variable efficacy from halted hair loss to no improvement. While patients did show success with HCQ treatment, there were no clear treatment patterns. Regimens ranged from HCQ monotherapy to combination treatments with other agents like steroids. Overall, HCQ should certainly be considered by clinicians as a treatment option for patient suffering from these hair disorders. While there is no standardized treatment, incorporation of HCQ should take into consideration individual patient characteristics, clinical judgment, and risks of side effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Skin appendage disorders - 9(2023), 6 vom: 26. Dez., Seite 416-422 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ravipati, Advaitaa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alopecia areata |
|---|
| Anmerkungen: |
Date Revised 08.12.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1159/000533583 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365494437 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365494437 | ||
| 003 | DE-627 | ||
| 005 | 20231227132300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000533583 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM365494437 | ||
| 035 | |a (NLM)38058539 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ravipati, Advaitaa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of Hydroxychloroquine in Hair Disorders |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 S. Karger AG, Basel. | ||
| 520 | |a Hydroxychloroquine (HCQ) is an antimalarial that is utilized to treat a range of dermatologic and autoimmune disorders. With its ability to alter immunologic mechanisms, it has been used to slow or halt the progression of hair loss in conditions secondary to autoimmune dysfunction. Lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and alopecia areata (AA) are hair disorders with underlying autoimmune components and no standardized treatment guidelines. We summarized the available literature on the use of HCQ to treat LPP, FFA, and AA. For all three conditions, HCQ showed variable efficacy from halted hair loss to no improvement. While patients did show success with HCQ treatment, there were no clear treatment patterns. Regimens ranged from HCQ monotherapy to combination treatments with other agents like steroids. Overall, HCQ should certainly be considered by clinicians as a treatment option for patient suffering from these hair disorders. While there is no standardized treatment, incorporation of HCQ should take into consideration individual patient characteristics, clinical judgment, and risks of side effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alopecia areata | |
| 650 | 4 | |a Antimalarials | |
| 650 | 4 | |a Frontal fibrosing alopecia | |
| 650 | 4 | |a Hair loss | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Lichen planopilaris | |
| 700 | 1 | |a Randolph, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Salhi, Waleed |e verfasserin |4 aut | |
| 700 | 1 | |a Tosti, Antonella |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Skin appendage disorders |d 2015 |g 9(2023), 6 vom: 26. Dez., Seite 416-422 |w (DE-627)NLM260272388 |x 2296-9195 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:6 |g day:26 |g month:12 |g pages:416-422 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000533583 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 6 |b 26 |c 12 |h 416-422 | ||